ABBV - AbbVie Inc.
89.48 0.00 (0.00%)
After hours: 4:58PM EST
| Previous Close | 91.53 |
| Open | 91.29 |
| Bid | 89.12 x 900 |
| Ask | 90.00 x 800 |
| Day's Range | 89.11 - 92.34 |
| 52 Week Range | 77.50 - 125.86 |
| Volume | 5,966,002 |
| Avg. Volume | 6,027,276 |
| Market Cap | 134.598B |
| Beta (3Y Monthly) | 1.73 |
| PE Ratio (TTM) | 18.69 |
| EPS (TTM) | 4.79 |
| Earnings Date | Jan 24, 2019 - Jan 28, 2019 |
| Forward Dividend & Yield | 4.28 (4.68%) |
| Ex-Dividend Date | 2019-01-14 |
| 1y Target Est | 100.58 |
- Zacks•2 hours ago
Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
CHMP gives positive opinion to Vertex's (VRTX) label expansion of Orkambi.
- GlobeNewswire•5 hours ago
CLASS ACTION UPDATE for ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Nov. 19, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- Business Wire•6 hours ago
DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (“AbbVie” or “the Company”) (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 25, 2013 and September 18, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 20, 2018.
- Zacks•8 hours ago
Should Value Investors Consider AbbVie (ABBV) Stock Now?
Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
- ACCESSWIRE•8 hours ago
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018
NEW YORK, NY / ACCESSWIRE / November 19, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") ...
Market Realist•8 hours agoHow Is Bausch Health’s Ortho Dermatologics Performing?
Bausch Health’s (BHC) wholly owned subsidiary Ortho Dermatologics generated revenues of $177.0 million in the third quarter. In the third quarter, Ortho Dermatologics’ net revenues remained flat compared to the third quarter of 2017. Ortho Dermatologics witnessed ~1% YoY organic revenue growth.
- GlobeNewswire•yesterday
SHAREHOLDER ALERT: TGTX ABBV MGTI HAS CPB CHGG ADNT GOOG NKTR SYF RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Nov. 18, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- Motley Fool•2 days ago
Why Abbvie Is Down 5% in 2018 So Far
Investors aboard this roller-coaster stock aren't sure they're having fun yet.
- ACCESSWIRE•3 days ago
4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 16, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 25, 2013 and September 18, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before November 20, 2018.
- Kiplinger•3 days ago
101 Best Dividend Stocks to Buy for 2019 and Beyond
Dependable dividend stocks that routinely grow their payouts are welcome in any environment. But they seem especially attractive nowadays. Stock market volatility is back with a vengeance. The Dow Jones Industrial Average went from powering ahead to an all-time high of 26,828 on Oct. 3 to losing 8% in the span of about three weeks. These kinds of rocky markets tend to give investors motion sickness. But they can add a dose of Dramamine to their portfolios - in the form of reliable dividend-growth stocks. "Dividend growers, which tend to be quality companies, have generally shown greater resilience in unsteady markets and could address concerns about dividend stocks in a rising-rate environment," write Tianyin Cheng, director of strategy and ESG Indices at S&P Dow Jones Indices; and Vinit Srivastava, head of strategy and ESG indices at S&P Dow Jones Indices. "This argument applies to not only to the U.S. large-cap space, but it also extends to small- and mid-cap segments and international markets." Dividend stocks - both at home and abroad - with long track records of rock-solid rising payments tend to generate superior returns over long periods of time and can help investors weather shorter periods of market turbulence. This is a look at the most reliable long-term dividend stocks in the world. Dubbed the "Dividend Aristocrats," they have raised dividends for at least five straight years (Canadian firms), 10 years (E.U.-based firms) or 25 years (U.S. companies). Such stocks provide reliable and rising income streams - and a sense of security that will help you sleep better at night. We've listed them here alphabetically; take a look. SEE ALSO: 25 Stocks Every Retiree Should Own
- ACCESSWIRE•3 days ago
WeissLaw LLP: AbbVie Inc. is the Subject of a Legal Investigation
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / WeissLawLLP, a national class action and shareholders' rights law firm with offices in New York, Los Angeles, and Atlanta, announces an investigation of AbbVie Inc. ("AbbVie" or the "Company") (ABBV). On September 18, 2018, a Bloomberg report revealed that the State of California had filed a lawsuit against the Company for its engagement in a kickback scheme.
- GlobeNewswire•3 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COCP, ABBV, CHGG, HON and DY
NEW YORK, Nov. 16, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- ACCESSWIRE•3 days ago
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") ...
Market Realist•3 days agoGauging Analysts’ Views on Clovis Stock
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
- Benzinga•3 days ago
11 NYSE- And NASDAQ-Listed Stocks With Cannabis Exposure
For investors who are seeking exposure to the cannabis industry but consider pure-play companies too risky, there are many other interesting investment opportunities. Pharma and biotech companies have ...
- Zacks•3 days ago
Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
- ACCESSWIRE•4 days ago
ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in AbbVie, Inc. to Contact the Firm
NEW YORK, NY / ACCESSWIRE / November 15, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AbbVie, Inc. ("AbbVie" or the "Company") (ABBV) of the November 20, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in AbbVie stock or options between October 25, 2013 and September 18, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/ABBV.There is no cost or obligation to you.
Market Realist•4 days agoExploring Clovis Oncology’s Operational Performance
Clovis Oncology (CLVS) incurred selling, general, and administrative expenses of $42.49 million in the third quarter compared to $35.01 million in the third quarter of 2017. This increase was due to higher commercialization activities for Rubraca and preparation for its expected launch in Europe.
Market Realist•4 days agoUnderstanding Clovis Oncology’s Gross Margin Trend
For 2018 and 2019, Clovis Oncology (CLVS) is expected to generate revenues of $88.79 million and $165.13 million, respectively, compared to its revenue of $55.51 million in 2017.
- Benzinga•4 days ago
The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 14) Vapotherm, Inc. (NYSE: VAPO )(listed following its IPO) ...
- ACCESSWIRE•5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. (''AbbVie'' or the ''Company'') (ABBV) and certain of its officers. The class action, filed in United States District Court, Northern District of Illinois, and index under 18-cv-06790, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired the publicly traded securities of AbbVie between October 25, 2013 and September 18, 2018, both dates inclusive (the ''Class Period''). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- Zacks•5 days ago
AbbVie (ABBV) Gains As Market Dips: What You Should Know
AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day.
- PR Newswire•5 days ago
AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
NORTH CHICAGO, Ill., Nov. 14, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NBIX), today presented for the first time additional results from two replicate pivotal Phase 3 clinical trials (ELARIS UF-1 (M12-815) and ELARIS UF-2 (M12-817)) evaluating the efficacy and safety of elagolix in women with uterine fibroids. These results were presented at the 47th American Association of Gynecologic Laparoscopists (AAGL) Global Congress on Minimally Invasive Gynecology in Las Vegas, NV. At the final month of the six-month treatment period, results demonstrated that elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg / norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding associated with uterine fibroids compared to placebo.
- GlobeNewswire•5 days ago
CLASS ACTION UPDATE for ABBV, CHGG and HTHT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Nov. 14, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- Zacks•5 days ago
AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study
AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.
